- Poster presentation
- Open Access
Low dose immunoglobulin g for treatment of severe sepsis and septic shock
Intensive Care Medicine Experimental volume 3, Article number: A433 (2015)
As an adjunctive treatment in sepsis, patients administered high-dose (0.9g/kg body weight) intravenous immunoglobulin G (IvIgG) did not have a significant survival benefit in a randomized control study (The SBITS study) (1). However, low-dose ivIgG (5g/day 3days) might have some utilities including earlier defervescence and improvements of clinical signs and symptoms (2).
In this retrospective cohort study of patients with severe sepsis and septic shock, we investigated whether low-dose IvIgG was associated with clinically important outcomes including ICU mortality and in-hospital mortality.
This study is a preplanned retrospective analysis of a large database created by Japan SEPTIC DIC study conducted in 41 ICUs. This study investigated associations between sepsis-related coagulopathy, anticoagulation therapies, and clinical outcomes of 3195 adult patients with severe sepsis and septic shock admitted to ICUs in Japan from January 2011 through December 2013. To estimate associations between IvIgG administration and mortalities, multivariable logistic regression modeling and propensity score-based matching were used for analysis with SPSS version 22.
IvIgG was administered in 976 patients (30.5%). Patients administered ivIgG had significantly higher APACHE II scores (24.2 ± 8.8 vs. 22.7 ± 8.6, P < 0.001), and SOFA scores at admission (10.4 ± 4.0 vs. 9.1 ± 4.0, P < 0.001). ICU mortality was higher in patients with IvIgG (23.1% vs. 18.4%, P = 0.003), but IvIgG was not associated with ICU mortality after adjustment for cofactors (OR 1.121, 95%CI 0.879-1.430, P = 0.358). In-hospital mortality in patients receiving IvIgG was similar to those not receiving IvIgG (34.7% vs 31.9% P = 0.118). In a propensity score-matched analysis, both ICU mortality and in-hospital mortality were not different between the groups (22.4% vs. 19.1%, P = 0.088; and 33.7% vs. 31.8%, P = 0.388, respectively).
In our retrospective analysis of a large cohort of severe sepsis and septic shock, administration of low-dose IvIgG as adjunctive therapy for patients with severe sepsis and septic shock was not associated with a reduction in ICU mortality and in-hospital mortality.
Werdan K, Pilz G, Bujdoso O, Fraunberger P, Neeser G, Schmieder RE, et al: Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study. Crit Care Med. 2007, 35 (12): 2693-2701. 10.1097/01.CCM.0000295426.37471.79.
Masaoka T: [Combination therapy of antibiotics and intravenous immunoglobulin]. Nihon Rinsho. 2001, 59 (4): 781-784.
About this article
Cite this article
Iizuka, Y., Sanui, M., Hayakawa, M. et al. Low dose immunoglobulin g for treatment of severe sepsis and septic shock. ICMx 3, A433 (2015) doi:10.1186/2197-425X-3-S1-A433
- Septic Shock
- Severe Sepsis
- Adjunctive Therapy
- Intravenous Immunoglobulin
- Anticoagulation Therapy